

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(10) International Publication Number  
**WO 2025/129601 A1**

(43) International Publication Date  
26 June 2025 (26.06.2025)

(51) International Patent Classification:

A61K 31/52 (2006.01) A61P 17/02 (2006.01)  
A61P 17/00 (2006.01)

(21) International Application Number:

PCT/CN2023/140870

(22) International Filing Date:

22 December 2023 (22.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicant: **ENERGENESIS BIOMEDICAL CO., LTD.**

[CN/CN]; 6F, -3, No. 21, Ln. 583, Ruiguang Rd., Neihu Dist., Taipei City, Taiwan 114 (CN).

(72) Inventors: **CHEN, Han-Min**; 6F, -3, No. 21, Ln. 583,

Ruiguang Rd., Neihu Dist., Taipei City, Taiwan 114 (CN).

**WANG, Hsin Chieh**; 6F, -3, No. 21, Ln. 583, Ruiguang Rd.,

Neihu Dist., Taipei City, Taiwan 114 (CN).

(74) Agent: **LUNG TIN INTELLECTUAL PROPERTY**

**AGENT LTD.**; 18th Floor, Tower B, Grand Place No. 5  
Huizhong Road, Chaoyang District, Beijing 100101 (CN).

(81) Designated States (*unless otherwise indicated, for every*

*kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every*

*kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

— *as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))*

**Published:**

— *with international search report (Art. 21(3))*

(54) Title: METHOD FOR TREATING EPIDERMOLYSIS BULLOSA

(57) Abstract: Provided is a method for treating epidermolysis bullosa in a subject in need thereof. The method includes administering to the subject an effective amount of adenine or a salt thereof. Also provided is a pharmaceutical composition for use in treating epidermolysis bullosa in a subject in need thereof.



WO 2025/129601 A1